Mechanical ventilation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to higher mechanical ventilation for RSV infection compared with motavizumab (high certainty).
1 finding from 1 review
Supplemental oxygen therapy for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in supplemental oxygen therapy for RSV infection compared with motavizumab (moderate certainty).
1 finding from 1 review
Number of children reporting any SAE · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in number of children reporting any SAE compared with motavizumab (high certainty).
1 finding from 1 review
All‐cause mortality · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Total RSV hospital days per 100 children · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower admission to ICU compared with placebo (high certainty).
1 finding from 1 review
Mechanical ventilation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
It is very uncertain whether palivizumab changes mechanical ventilation for RSV infection compared with placebo (very low certainty).
1 finding from 1 review
Supplemental oxygen therapy for RSV infection · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Number of children reporting any SAE · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower number of children reporting any SAE compared with placebo (high certainty).
1 finding from 1 review
Hospitalisation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in hospitalisation for RSV infection compared with motavizumab (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in all‐cause mortality compared with motavizumab (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality Mortality at latest · heart transplant recipients
The intervention showed no clear difference in mortality Mortality at latest (low certainty).
1 finding from 1 review
CMV infection · heart transplant recipients
Interleukin‐2 RA showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with no induction (low certainty).
1 finding from 1 review
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients
Interleukin‐2 RA showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with no induction (low certainty).
1 finding from 1 review
Cancer · heart transplant recipients
Interleukin‐2 RA showed no clear difference in cancer Number of participants diagnosed with cancer compared with no induction (low certainty).
1 finding from 1 review
Intervention not reported
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
The intervention showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy (low certainty).
1 finding from 1 review
Intervention not reported
Infection Number of participants diagnosed with infection · heart transplant recipients
The intervention showed no clear difference in infection Number of participants diagnosed with infection (low certainty).
1 finding from 1 review
Intervention not reported
Cytomegalovirus infection Number of patients diagnosed with CMV infection · heart transplant recipients
The intervention showed no clear difference in cytomegalovirus infection Number of patients diagnosed with CMV… (low certainty).
1 finding from 1 review
Intervention not reported
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients
The intervention showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… (low certainty).
1 finding from 1 review
Intervention not reported
Cancer Number of participants diagnosed with cancer · heart transplant recipients
The intervention showed no clear difference in cancer Number of participants diagnosed with cancer (low certainty).
1 finding from 1 review